FibroGen (FGEN) PT Raised to $65 at Citi, Remains Top Pick
Tweet Send to a Friend
Citi raised its price target on FibroGen (NASDAQ: FGEN) to $65.00 (from $48.00) while maintaining a Buy rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
